Algeta ASA is focused on the development of cancer therapeutics, particularly known for its product Xofigo, an alpha particle-emitting radioactive therapeutic agent for treating castration-resistant prostate cancer with symptomatic bone metastases
Algeta ASA is focused on the development of cancer therapeutics, particularly known for its product Xofigo, an alpha particle-emitting radioactive therapeutic agent for treating castration-resistant prostate cancer with symptomatic bone metastases.